Industry: Healthcare
Published Date: March-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 257
Report ID: PMRREP13594
The global life sciences aggregate-spending market was pegged at US$ 974.2 Mn in 2021, with a projected CAGR of 10% for the forecast period (2022-2032), which implies encouraging market growth. Detailed industry analysis reveals that revenue from life sciences aggregate-spend reporting will surge to a market valuation of US$ 2.75 Bn by the end of 2032.
| Attribute | Key Insights |
|---|---|
|
Life Sciences Aggregate-Spending Market Size (2022) |
US$ 1.06 Bn |
|
Projected Market Value (2032) |
US$ 2.75 Bn |
|
Global Market Growth Rate (2022-2032) |
10% CAGR |
|
Share of Top 5 Countries |
91.1% |
According to detailed industry analysis by Persistence Market Research, medium-sized businesses captured more than 43% market share by revenue in the life sciences aggregate-spending market in 2021.
Overall, revenue from life sciences aggregate-spending solutions accounted for 16.3% share of the global life sciences software market value in 2021.
The global market for life sciences aggregate-spending exhibited swift growth and expanded at a CAGR of 9.1% over the last five years (2017-2021).
The National Healthcare Spend (NHE) of the United States was the US$ 4.1 trillion in 2020, according to CMS, with per capita expenditure of US$ 12,530. In 2019, NHE was US$ 3.8 trillion, with per capita spending of US$ 11,582.
Every year, healthcare spending in the United States rises, indicating a well-developed healthcare infrastructure and more accessibility to healthcare. This will also be a driving force for the life sciences aggregate-spending industry, as it represents numerous lucrative opportunities for key players as well as new market entrants.
Unethical methods such as gifting and delivering non-monetary benefits to healthcare professionals by pharmaceutical and medical device firms affect their prescription patterns, which influences the cost of products in the market. To prevent such unethical conduct, regulatory organizations in countries all over the world are enacting legislation similar to the Sunshine Law.
In the life sciences aggregate-spending market, third-party solution providers are critical as they provide end-to-end services and help with the aggregate-spend reporting and compliance needs of pharma, biotech, and medical device manufacturing companies.
As a result, there is robust demand for third-party providers among healthcare organizations, which will elevate the market value for third-party solution providers in the global life sciences aggregate-spend reporting market.
The market expects to see considerable growth and expand 2.75X by the end of 2032.
“Growing Number of MSMEs in Healthcare Industry”
Small- and medium-sized businesses provide great potential for expanding a country’s economies. They provide employment opportunities on a large scale.
Growing number of MSMEs will provide many lucrative opportunities for key life sciences aggregate-spending solution providers.
To strengthen their market position, several pharmaceutical companies, medical device makers, and healthcare IT companies are focusing their efforts on growing their businesses overseas. Because of their market presence in several areas, they need a support organization that can handle their aggregate-spend data across geographies.
High volume of investments in healthcare will boost demand for third-party solution providers globally over the next few years and thereby offer beneficial openings for new entrants into this market.
“Non-availability of Structured Physician Data”
Data collection organizations have their ways to collect and store data. This also applies to various institutions that collect doctors' data. For example, electronic medical records contain important information about doctors and patients but are usually in unstructured data format.
Unstructured data can lead to more information, but given its tedious nature, takes much longer to process. Structured data availability is difficult because medical institutions work with a large number of doctors.
Aggregate-spend reporting involves huge amounts of transactional data of an organization over an entire year. Usually, these organizations use spreadsheets to record this data. Such an amount of data can lead to operational errors by the employees handling them.
Errors in data collection can result in mistakes in reporting. This can also prove to be a restraining factor for the life sciences aggregate-spending market.
Why are Aggregate-Spend Reporting Solution Providers Targeting the U.S. Market?
“Well-developed Healthcare Infrastructure Makes the U.S. Market Attractive”
North America accounted for 84.5% market share in terms of revenue of the global aggregate-spending market during 2021, out of which, the U.S. captured more than 97% of the regional market share.
Highly favourable regulatory environment in the nation facilitates the investment and growth of many pharma, life sciences, and medical device manufacturing companies.
How is Demand for Life Sciences Aggregate-Spending Shaping Up in the U.K.?
“Market to Proliferate Due to High Spending on Life Sciences in the Country”
According to a report published by PwC, the life sciences industry supports almost half a million jobs in the U.K. The U.K. life sciences industry plays a key role in addressing long-term health issues in both, the U.K. and the broader global healthcare market.
Since the life sciences sector directly relates to the aggregate-spending sector, the U.K. accounted for 20.4% market share of the Europe life sciences aggregate-spending market in terms of revenue in 2021.
Why is Japan an Emerging Market for Life Sciences Aggregate-spend Reporting?
“Favourable Regulations Align Market Growth in Japan”
The Japan Pharmaceutical Manufacturer’s Association (JPMA) and Japan Federation of Medical Device Associations (JFMDA) regulate the transparency laws in Japan. All pharmaceutical member companies of JPMA and medical device members companies of JFMDA are required to publish their aggregate spend report in Japan.
Pharma companies and medical device manufacturers are required to report research and development expenses, academic research support expenses, manuscripts or writing fees, information provision-related expenses, and other payments.
Due to the aforementioned reasons, Japan proves to be one of the emerging countries in the market and accounted for 41.7% market share by revenue in the APAC life sciences aggregate-spending market in 2021.
Will Third-party Solution Providers Drive Market Growth?
“High Demand for Third-party Solution Providers”
Third-party solution providers of life sciences aggregate-spending are important as they are well-equipped to cater to global, domestic, or country-specific demands of various pharma, biotech, life sciences, and medical device manufacturers around the world.
This segment accounted for more than 36% of the global market share in terms of revenue in 2021, and is set to surge at a CAGR of 10.7% over the forecast period (2022-2032).
Which Deployment Type Exhibits Higher Market Share?
“Cloud-based Deployment Remains Preferred Choice”
Cloud-based deployment solutions captured more than 64% market share in terms of revenue in 2021.
Ease of data collection and highlighting and one-stop solution for all healthcare providers are the attractive capabilities of this type of deployment that explains the high market share.
Which Businesses Enjoys Most Benefits of Life Sciences Aggregate-spending?
“Medium businesses are the largest shareholders!”
Medium-sized businesses around the world offer lucrative opportunities for market growth, for individual job seekers and for governments to expand their economies. They also require external support to grow their business and often contribute a large portion to the country’s economy.
In the life sciences aggregate-spending solutions market, medium-sized businesses accounted for over 43% market share by revenue in 2021.
Global providers of life sciences aggregate-spending solutions are undertaking various efforts to expand their market presence and goodwill through strategic partnerships, acquiring smaller companies, and launching innovative products.
| Attribute | Details |
|---|---|
|
Forecast Period |
2022-2032 |
|
Historical Data Available for |
2017-2021 |
|
Market Analysis |
US$ Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
Life Sciences Aggregate-Spending Market by Solution:
Life Sciences Aggregate-Spending Market by Deployment:
Life Sciences Aggregate-Spending Market by Business Type:
Life Sciences Aggregate-Spending Market by End User:
Life Sciences Aggregate-Spending Market by Region:
To know more about delivery timeline for this report Contact Sales
The global life sciences aggregate-spending market was valued at US$ 974.2 Mn in 2021 and is expected to grow 2.75X by 2032.
Life sciences aggregate-spending solution demand is set to witness a high growth rate of 10% over the forecast period and be valued at US$ 2.75 Bn by 2032.
The market expanded at 9.1% during 2017 to 2021.
Qordata, Porzio Life Sciencess, LLC, MedPro Systems LLC, IQVIA Inc, MediCompli and MMIS, Inc are key providers of life sciences aggregate-spending reporting solutions.
Third-party solution providers are driving most demand and held 36.4% market share in 2021.
The U.S., Japan, Australia, Canada, and France will drive most demand growth of life sciences aggregate-spending solutions.
The U.S. accounts for 97.5% share of the North America life sciences aggregate-spending market.
The Europe life sciences aggregate-spending market is expected to record a CAGR of 9.4%.
The U.S. and France are major countries in the global life sciences aggregate-spending market.
The Japanese market held a share of 41.7% in APAC in 2021.
